Aldeyra Therapeutics, Inc. earnings per share and revenue
On Nov 05, 2025, ALDX reported earnings of -0.13 USD per share (EPS) for Q3 25, beating the estimate of -0.24 USD, resulting in a 47.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.43% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.17 USD, with revenue projected to reach 24.73 million USD, implying an increase of 30.77% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Aldeyra Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Aldeyra Therapeutics, Inc. reported EPS of -$0.13, beating estimates by 47.98%, and revenue of $0.00, 0% as expectations.
How did the market react to Aldeyra Therapeutics, Inc.'s Q3 2025 earnings?
The stock price moved down -2.43%, changed from $4.93 before the earnings release to $4.81 the day after.
When is Aldeyra Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Feb 26, 2026.
What are the forecasts for Aldeyra Therapeutics, Inc.'s next earnings report?
Based on 8
analysts, Aldeyra Therapeutics, Inc. is expected to report EPS of -$0.17 and revenue of $24.73M for Q4 2025.